Клинические аспекты диагностики и лечения остеопороза у женщин в постменопаузе


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Менопаузальный переход характеризуется ускоренной потерей костной массы, повышением риска деформаций скелета и низкоэнергетических переломов. Основной причиной постменопаузального остеопороза является стойкое снижение и прекращение эстроген-продуцирующей функции яичников. Клиницистам, которые занимаются проблемой остеопороза, следует помнить, что нельзя ставить знак равенства между терминами «постменопаузальный остеопороз» и «остеопороз у женщин в постменопаузе», т.к. у пациенток в постменопаузе могут быть другие заболевания и факторы, ускоряющие потерю минеральной плотности костной ткани, вызванную снижением уровня эстрогенов, тем самым повышая риск развития остеопороза и низкоэнергетических переломов (вторичный остеопороз).

Полный текст

Доступ закрыт

Об авторах

Сергей Сергеевич Апетов

ООО «Центр эндокринного здоровья»

Email: apetov@rambler.ru
к.м.н., врач-эндокринолог, акушер-гинеколог Челябинск, Россия

В. В Апетова

ООО «Центр эндокринного здоровья»

Челябинск, Россия

Список литературы

  1. URL: https://rosstat.gov.ru/compendium/document/13285
  2. Kristensen P.K., Perez-Vicente R., Leckie G., et al. Disentangling the contribution of hospitals and municipalities for understanding patient level differences in one-year mortality risk after hip-fracture: a cross-classified multilevel analysis in Sweden. PLoS One. 2020;15(6):e0234041. doi: 10.1371/journal.pone.0234041.
  3. Meyer I., Morgan S.L., Markiand A.D., et al. Peivic floor disorder symptoms and bone strength in postmenopausal women. Int Urogynecol J. 2020;31(9):1777-84. doi: 10.1007/s00192-020-04254-z.
  4. Curhan S.G., Stankovic K., Halpin C., et al. Osteoporosis, bisphosphonate use, and risk of moderate or worse hearing loss in women. J Am Geriatr Soc. 2021 May 24. Doi: 10.1111/ jgs.17275. Online ahead of print.
  5. Park J., Yoon YE., Kim K.M., et al. Prognostic value of lower bone mineral density in predicting adverse cardiovascular disease in Asian women. Heart. 2021 May 7: heartjnl-2020-318764. doi: 10.1136/heartjnl-2020-318764. Online ahead of print.
  6. Sumino H., Ichikawa S., Abe M., et al. Effects of aging and postmenopausal hypoestrogenism on skin elasticity and bone mineral density in Japanese women. Endocr J. 2004;51(2):159-64. doi: 10.1507/endocrj.51.159.
  7. Tomasevic-Todorovic S., Vazic A., et al. Comparative assessment of fracture risk among osteoporosis and osteopenia patients: a cross-sectional study.O pen Access Rheumatol. 2018;10:61-6. doi: 10.2147/OARRR.S151307.
  8. Wattanachanya L., Pongchaiyakul C. Prevalence and risk factors of morphometric vertebral fracture in apparently healthy osteopenic postmenopausal Thai women. Menopause. 2020;28(1):12-7. doi: 10.1097/GME.0000000000001634.
  9. Ji M.X., Yu Q. Primary osteoporosis in postmenopausal women. Chronic Dis Transl Med. 2015;1(1):9-13. Doi: 10.1016/j. cdtm.2015.02.006.
  10. Santen R.J., Pinkerton J.V, Liu J.H., et al. Workshop on normal reference ranges for estradiol in postmenopausal women, September 2019, Chicago, Illinois. Menopause. 2020;27(6):614-doi: 10.1097/GME.0000000000001556.
  11. Singh P, Singh M., Khinda R., et al. Genetic Scores of eNOS, ACE and VEGFA Genes Are Predictive of Endothelial Dysfunction Associated Osteoporosis in Postmenopausal Women. Int J Environ Res Public Health. 2021;18:972. Doi: 10.3390/ ijerph18030972.
  12. Mendelsohn M.E., Karas R.H. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801-11. Doi: 10.1056/ NEJM199906103402306.
  13. Watson E.C., Adams R.H. Biology of Bone: The Vasculature of the Skeletal System. Cold Spring Harb Perspect Med. 2018;8(7):031559. doi: 10.1101/cshperspect.a031559.
  14. Tomlinson R.E., Silva M.J. Skeletal Blood Flow in Bone Repair and Maintenance. Bone Res. 2013;1:311-22. doi: 10.4248/BR201304002.
  15. Marenzana M., Arnett T.R. The Key Role of the Blood Supply to Bone. Bone Res. 2013;1:203-215. doi: 10.4248/BR201303001
  16. Rucci N. Molecular biology of bone remodelling. Clin. Cases Miner. Bone Metab. 2008;5:49-56.
  17. Blum A., Zarqh O., Peleg A., et al. Vascular inflammation and endothelial dysfunction in fracture healing. Am J Orthop Belle Mead NJ. 2012;41:87-91.
  18. Zhao Y, Xie L. Unique bone marrow blood vessels couple angiogenesis and osteogenesis in bone homeostasis and diseases. Ann NY Acad Sci. 2020;1474:5-14. doi: 10.1111/nyas.14348.
  19. Finkelstein J.S, Brockwell S.E., Mehta V., et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab. 2008;93(3):861-68. doi: 10.1210/jc.2007-1876.
  20. Tella S.H., Gallagher J.C. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol. 2014;142:155-70. Doi: 10.1016/j. jsbmb.2013.09.008.
  21. Parfitt A.M. The coupling of bone formation to bone resorption: a critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis. Metab Bone Dis Relat Res. 1982;4(1):1-6. doi: 10.1016/0221-8747(82)90002-9.
  22. Yoo J.E., Shin D.W., Han K., et al. Association of Female Reproductive Factors With Incidence of Fracture Among Postmenopausal Women in Korea. JAMA Netw Open. 2021;4(1):e2030405. doi: 10.1001/jamanetworkopen.2020.30405.
  23. Ahmeidat A., Bhattacharya S., Luben R.N., et al. Long-term effects of gestational diabetes on bone mineral density and fracture risk: Analysis of the Norfolk cohort of the European Prospective Invest.igat.ion into Cancer (EPIC-Norfolk) population-based study Maturitas. 2021;144:68-doi: 10.1016/j.maturitas.2020.11.005.
  24. Lee E.N. Effects of Parity and Breastfeeding Duration on Bone Density in Postmenopausal Women. Asian Nurs Res (Korean Soc Nurs Sci). 2019;13(2):161-doi: 10.1016/j.anr.2019.04.002.
  25. Polyzos S.A., Anastasilakis A.D., Efstathiadou Z.A., et al. Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations. Maturitas 2021;147:19-25. Doi: 10.1016/j. maturitas.2021.02.007.
  26. Abbasi M., Farzam S.A., Mamaghani Z., Yazdi Z. Relationship between metabolic syndrome and its components with bone densitometry in postmenopausal women. Diabetes Metab Syndr. 2017;11(Suppl 1):S73-S76. Doi: 10.1016/j. dsx.2016.12.008.
  27. Caglayan E.K., Engin-Ustun Y, Sari N., et al. Evaluation of bone density measurement in type 2 diabetic postmenopausal women with hypertension and hyperlipidemia. J Menopausal Med. 2015;21(1):36-40. Doi: 10.6118/ jmm.2015.21.1.36.
  28. Turan E., Kizilkaya H., Aral Y. Is metabolic syndrome related to postmenopausal osteoporosis? A retrospective study. Arch Clin Exp Med 2018;3(2):71-4. doi: 10.25000/acem.419847.
  29. Seimon R.V, Wild-Taylor A.L., Keating S.E., et al. Effect of Weight Loss via Severe vs Moderate Energy Restriction on Lean Mass and Body Composition Among Postmenopausal Women With Obesity: The TEMPO Diet Randomized Clinical Trial. JAMA Netw Open. 2019;2(10):e1913733. Doi: 10.1001/ jamanetworkopen.2019.13733.
  30. Paschou S.A., Dede A.D., Anagnostis PG., et al. Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management. J Clin Endocrinol Metab. 2017;102(10):3621-34. Doi: 10.1210/ jc.2017-00042.
  31. Leutner M., Matzhold C., Bellah L., et al. Diagnosis of osteoporosis in statin-treated patients is dose-dependent. Ann Rheum Dis. 2019;78:1706-11. doi: 10.1136/annrheumdis-2019-215714.
  32. Sugitani I., Fujimoto Y. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study. Surgery. 2011;150(6):1250-57. Doi: 10.1016/j. surg.2011.09.013.
  33. Kwak D., Ha J., Won Y., et al. Effects of thyroid-stimulating hormone suppression after thyroidectomy for thyroid cancer on bone mineral density in postmenopausal women: a systematic review and meta-analysis. BMJ Open. 2021;11(5):e043007. Doi: 10.1136/ bmjopen-2020-043007.
  34. Percivale A., Gnerre P, Damonte G., et al. Primary hyperparathyroidism: epidemiology, clinical features, diagnostic tools and current management. Italian Journal of Medicine. 2015,9(4),330-45.
  35. Desai M.K., Brinton R.D. Autoimmune Disease in Women: Endocrine Transition and Risk Across the Lifespan. Front Endocrinol (Lausanne). 2019;10:265. doi: 10.3389/fendo.2019.00265.
  36. Maldonado G., Messina O., Moreno M., Ros C. Osteoporosis in rheumatic diseases and glucocorticoid induced. Rev Osteoporos Metab Miner. 2017;9(1):38-49.
  37. Fardet L., Petersen I., Nazareth I. Monitoring of patients on long-term glucocorticoid therapy: a population-based cohort study. Medicine (Baltimore). 2015;94(15):e647. doi: 10.1097/ MD.0000000000000647.
  38. Overman R.A., Yeh J.Y., Deal C.L. Prevalence of oral glucocortidoid usage in the United States: a general population perspective. Arthr Care Res. 2013;65:294-98. doi: 10.1002/acr.21796.
  39. Silverman S., Curtis J., Saag K., et al. International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study. Osteoporos Int. 2015;26(1):419-20. doi: 10.1007/s00198-014-2883-2.
  40. Chotiyarnwong P, McCloskey E.V Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol. 2020;16(8):437-47. doi: 10.1038/s41574-020-0341-0.
  41. Triebner K., Matulonga B., Johannessen A., et al. Menopause Is Associated with Accelerated Lung Function Decline. Am J Respir Crit Care Med. 2017;195(8):1058-65. doi: 10.1164/ rccm.201605-0968OC.
  42. Swaminathan K., Flynn R., Garton M., et al. Search for secondary osteoporosis: are Z scores useful predictors? Postgrad Med J. 2009;85(999):38-9. doi: 10.1136/pgmj.2007.065748.
  43. Cauley J.A., Robbins J., Chen Z., et al. Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003;290(: 3doi: 10.1001/jama.290.13.1729.
  44. Jackson R.D., Wactawski-Wende J., LaCroix A.Z., et al.; Women's Health Initiative Investigators. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial. J Bone Miner Res. 2006;21(6):817-28. doi: 10.1359/ jbmr.060312.
  45. Zhu L., Jiang X., Sun Y, Shu W. Effect of hormone therapy on the risk of bone fractures: a systematic review and meta-analysis of randomized controlled trials. Menopause. 2016;23(4):461-70. doi: 10.1097/GME.0000000000000519.
  46. Silverstein W.K., Zipursky J.S., Shadowitz S. Closing the Osteoporosis Care Gap: A Teachable Moment. JAMA Intern Med. Published online October 18, 2021. doi: 10.1001/jamainternmed.2021.5972.
  47. Eastell R., Rosen C.J., Black D.M., et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104(5):1595-1622. Doi: 10.1210/ jc.2019-00221.
  48. Vestergaard P. Risk of newly diagnosed type 2 diabetes is reduced in users of alendronate. Calcif Tissue Int. 2011;89(4):265-70. Doi: 10.1007/ s00223-011-9515-z.
  49. Peng R., Liang X., Zhang G., et al. Association Use of Bisphosphonates with RiskofBreastCancer: A MetaAnalysis. Biomed Res Int. 2020;2020:5606573. doi: 10.1155/2020/5606573.
  50. Burt L.A., Billington E.O., Rose M.S., et al. Adverse Effects of High-Dose Vitamin D Supplementation on Volumetric Bone Density Are Greater in Females than Males. J Bone Miner Res. 2020;35(12):2404-14. doi: 10.1002/jbmr.4152.
  51. Zarei A., Morovat A., Javaid K., Brown C.P Vitamin D receptor expression in human bone tissue and dose-dependent activation in resorbing osteoclasts. Bone Res. 2016;4:16030. doi: 10.1038/boneres.2016.30.
  52. Bolland M.J., House M.E., Horne A.M., et al. Nitrates Do Not Affect Bone Density or Bone Turnover in Postmenopausal Women: A Randomized Controlled Trial. J Bone Miner Res. 6020;3-(4);1040-47.Doi: 10.1002/ jbmr.3982.
  53. El-Sergany M., Shahba A., Al-Ahwal L. Exercise versus Estrogen Therapy in Osteoporotic Postmenopausal Women with Endothelial Dysfunction. J Am Sci. 2010;6(10):1013-18.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2021